Value through Innovation27 July 2016

What is a lay summary?

Lay Summaries and Lay Summary Videos

  • PRAXBIND ® - Hemorrhage
    Clinical Study Number 1321.3
    Study Indication Hemorrhage
    Product PRAXBIND ®
    Generic Name Idarucizumab
    Lab Code
    Clinical Phase III
    Study Title

    A Phase III, case series clinical study of the reversal of the anticoagulant effects of dabigatran by intravenous administration of 5.0 g idarucizumab (BI 655075) in patients treated with dabigatran etexilate who have uncontrolled bleeding or require emergency surgery or procedures. RE-VERSE-AD (A study of the RE-VERSal Effects of Idarucizumab on Active Dabigatran) trial

    Study Document
    Lay summary 1321.3 english